Brief: Neovacs H1 net loss widens to 8.1 million euros
27/10/2017 16:45
Oct 27 (Reuters) - NEOVACS SA ALNEV.PA :
* H1 NET LOSS EUR 8.1 MILLION VERSUS LOSS OF EUR 6.8
MILLION YEAR AGO
* H1 OPERATING LOSS EUR 10.2 MILLION VERSUS LOSS OF EUR
7.9 MILLION YEAR AGO
* H1 REVENUE EUR 0.5 MILLION VERSUS EUR 0.1 MILLION YEAR
AGO
* CASH AND CASH EQUIVALENTS AT JUNE 30, 2017, AMOUNTED TO
EUR 1.8 MLN
* TO OBTAIN RESULTS FROM PHASE IIB CLINICAL TRIAL IN LUPUS
IN JUNE 2018
Source text for Eikon: ID:nGNE24NCZb
Further company coverage: ALNEV.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Neovacs SA
See all newsBrief: Neovacs And FOCH Hospital Commit To Partnership On Research In Pneumology And Allergology
Brief: Neovacs Presented Latest Results On Its Vaccine Candidates Targeting Allergies
Brief: Neovacs H1 Gross Cash Position Down At EUR 6.2 Mln
Brief: Neovacs: Signature Of Trust Agreement For Equitization Of Bonds Redeemable In Shares With Share Warrants
Brief: Neovacs Launches A Public Offering Of Bonds Redeemable In Shares With Stock Warrants